Although there is paucity of research of the long-term safety of GLP-1 analogues in cancer survivors, it is a reasonable option in diabetic cancer survivors with excess body weight or those who are normoglycemic but failed other weight reduction measures. The gene discussed is GLP1R; the disease is diabetes mellitus.